CSL Centenary Fellowships Support Researchers Seeking to Beat Leukemia and Improve Our Understanding of Alzheimer’s Disease

By Andrea Douglas, Ph.D.
January 17, 2017

Steven Lane

We often say innovation is in our DNA at CSL. But without financial and scientific commitment to a dynamic R&D program, innovation would not be possible. The long-term sustainability of CSL requires a full R&D pipeline of high-quality prospective products. This is why CSL has invested $2.3 billion in R&D over the last five years and why we support research teams all over the world. It is also the reason we are committed to identifying and supporting the best and brightest biomedical researchers in Australia.

Our commitment to R&D extends to the broader scientific community beyond the CSL laboratories. An example of this is the CSL Centenary Fellowship program. This $AUD 25 million program awards two, five-year $1.25 million fellowships each year to early/mid-career Australian medical researchers, who are working on world-class discovery or translational research in the areas of rare and serious diseases, immunology and inflammation.

Continue reading

CSL Behring Helps Fuel Switzerland’s Fertile Innovation Ecosystem

Known for our life-changing biotherapies, CSL Behring is one of a number of companies that benefit from the Swiss model of vocational education.


By Jasmin Joller

December 22, 2016

At our manufacturing facility in Bern, we’ve been receiving visits from dignitaries and business heads from around the world such as U.S. Secretary of Labor Thomas E. Perez, President of Poland Andrzej Duda, Microsoft President Brad Smith and the European-Australian Business Council.

Usually we attract attention because of our world-class biotherapies, or because we’ve been recognized as an employer of choice in Switzerland. Now we’re attracting attention because it’s widely recognized that Switzerland has set quite a standard for occupational learning programs, and CSL Behring is a shining example of that standard.

Continue reading

Working Each Day As If People’s Lives Depend on Us

At CSL Behring, a Job Isn’t Just a Job

Recruitment #4
(Photo by Patrick Fore)

By Elizabeth Walker

December 14, 2016

I’m often asked, “What makes CSL Behring a great place to work?” For me, it’s about our patient centricity and company purpose. We develop and deliver innovative specialty biotherapies, helping people with life-threatening conditions live full lives. That’s an inspiring responsibility. Our CEO Paul Perreault encourages us to work each day as if people’s lives depend on us ‒ because they do. I can’t think of a better reason for coming to work every day.

Continue reading

What Will Healthcare Look Like in 50 to 100 Years?

If we focus on innovation and sustainability, healthcare will evolve in ways that are in sync with the changing needs of patients, the economy and global politics.

BioFest 2016

The following post is excerpted from Paul Perreault’s remarks at International BioFest 2016 in Melbourne, Australia.

December 6, 2016

Healthcare statisticians tell us that the first person who will live to 150 years of age has already been born. Considering human biology and the challenges we would need to overcome, doubling our life expectancy at first seems fanciful. But with our understanding of science and the refined art of personalized medicine, 150 may be reasonable.

In fact, our understanding of human biology is expanding at an exponential rate. Ten years ago it took the world’s greatest minds 10 years to map the human genome. Now it takes one day. Even for those of us in the healthcare sector, it is virtually impossible to predict what healthcare will look like in 50 or 100 years. But there are constants to guide us.

Continue reading

Coagulation Research Award Taps Brain Power and Vision of New Generation of Researchers

The CSL Behring Professor Heimburger Award is helping to ensure young researchers around the world have the opportunity to bring their innovative ideas to the forefront.

October 1­­7, 2016


We are seeing some exciting research as CSL Behring delivers on our promise to advance research and innovation through grants such as the Heimburger Award.

This is particularly important for young researchers working in clinics who often don’t have time to raise money for their research. Adding to the challenge is the fact that government funding of orphan disease research is often difficult to obtain.

Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.